Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted Cash from Financing Activities of $79.4 million for Q2 2026, up 234.38% on a QoQ basis from -$59.1 million in Q1 2026, and up 290.37% year-over-year from $20.3 million in Q2 2025.
Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals has reported Cash from Financing Activities for 10 years, with the latest figure at $79.4 million in Q2 2026.
- On a quarterly basis, Cash from Financing Activities rose 290.37% year-over-year to $79.4 million in Q2 2026; TTM through Jun 2026 was $69.6 million, a 129.7% increase from a year earlier, with the FY2025 full-year figure at -$31.5 million, up 85.11% from the prior year.
- Cash from Financing Activities was $79.4 million for Q2 2026 at Amneal Pharmaceuticals, up from -$59.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $79.4 million in Q2 2026, with the low at -$100.8 million in Q4 2023.
- Average Cash from Financing Activities over 5 years is -$30.1 million, with a median of -$37.1 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 354.87% in 2023, then jumped 290.37% in 2026.
- Over 5 years, Cash from Financing Activities stood at -$22.2 million in 2022, then plunged by 354.87% to -$100.8 million in 2023, then soared by 39.3% to -$61.2 million in 2024, then soared by 83.47% to -$10.1 million in 2025, then surged by 884.2% to $79.4 million in 2026.
- The last three Cash from Financing Activities figures came in at $79.4 million (Q2 2026), -$59.1 million (Q1 2026), and -$10.1 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 46.72 Bn | 43.07 Bn | 2.15 Bn | -1.00 Mn |
| 2 | Viatris | 19.64 Bn | 18.75 Bn | 1.46 Bn | -1.24 Bn |
| 3 | Dr Reddys Laboratories | 10.36 Bn | 10.22 Bn | 396.53 Mn | -75.18 Mn |
| 4 | Amneal Pharmaceuticals | 6.44 Bn | 6.39 Bn | 334.51 Mn | 79.36 Mn |
| 5 | Bausch Health Companies | 2.11 Bn | 1.24 Bn | 2.10 Bn | -49.00 Mn |
| 6 | Ani Pharmaceuticals | 1.88 Bn | 1.52 Bn | 165.89 Mn | -4.65 Mn |
| 7 | Alvotech | 1.83 Bn | 1.69 Bn | 2.56 Mn | 143.38 Mn |
| 8 | Amphastar Pharmaceuticals | 1.04 Bn | 751.07 Mn | 93.47 Mn | -43.54 Mn |
| 9 | Fennec Pharmaceuticals | 382.22 Mn | 340.97 Mn | 17.15 Mn | - |
| 10 | NutriBand | 94.45 Mn | 91.03 Mn | 181,874.00 | 430.00 |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 79.36 Mn |
| Mar 31, 2026 | -59.06 Mn |
| Dec 31, 2025 | -10.12 Mn |
| Sep 30, 2025 | 59.44 Mn |
| Jun 30, 2025 | -41.69 Mn |
| Mar 31, 2025 | -39.17 Mn |
| Dec 31, 2024 | -61.20 Mn |
| Sep 30, 2024 | -92.35 Mn |
| Jun 30, 2024 | -35.09 Mn |
| Mar 31, 2024 | -23.16 Mn |
| Dec 31, 2023 | -100.83 Mn |
| Sep 30, 2023 | -86.59 Mn |
| Jun 30, 2023 | -12.26 Mn |
| Mar 31, 2023 | -12.90 Mn |
| Dec 31, 2022 | -22.17 Mn |
| Sep 30, 2022 | -46.13 Mn |
| Jun 30, 2022 | 23.25 Mn |
| Mar 31, 2022 | -61.57 Mn |
| Dec 31, 2021 | -30.35 Mn |
| Sep 30, 2021 | -43.56 Mn |
Amneal Pharmaceuticals Cash from Financing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=AMRX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-financing-activities", "ticker": "AMRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=AMRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();